Bluebird bio Inc (NASDAQ:BLUE)’s traded shares stood at 1.51 million during the latest session, with the company’s beta value hitting 0.75. At the last check today, the stock’s price was $0.58, to imply an increase of 0.26% or $0.0 in intraday trading. The BLUE share’s 52-week high remains $5.53, putting it -853.45% down since that peak but still an impressive 10.34% since price per share fell to its 52-week low of $0.52. The company has a valuation of $112.43M, with an average of 8.01 million shares in intraday trading volume over the past 10 days and average of 7.29 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Bluebird bio Inc (BLUE), translating to a mean rating of 2.80. Of 4 analyst(s) looking at the stock, 1 analyst(s) give BLUE a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.61.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bluebird bio Inc (NASDAQ:BLUE) trade information
After registering a 0.26% upside in the latest session, Bluebird bio Inc (BLUE) has traded red over the past five days. The 5-day price performance for the stock is 2.57%, and -44.97% over 30 days. With these gigs, the year-to-date price performance is -57.73%. Short interest in Bluebird bio Inc (NASDAQ:BLUE) saw shorts transact 41.14 million shares and set a 5.81 days time to cover.
The extremes give us $5 and $25 for target low and target high price respectively. As such, BLUE has been trading -4210.34% off suggested target high and -762.07% from its likely low.
Bluebird bio Inc (BLUE) estimates and forecasts
Revenue is forecast to shrink -260.50% this quarter before falling -290.50% for the next one. The rating firms project that company’s revenue will grow 798.50% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 9.66M. Meanwhile, for the current quarter, a total of 7 analyst(s) estimate revenue growth to 19.04M.Earnings reports from the last fiscal year show that sales brought in 62k and 2.38M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 15,480.60% before jumping 699.70% in the following quarter.
BLUE Dividends
Bluebird bio Inc has its next earnings report out on 2023-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
Bluebird bio Inc insiders hold 0.36% of total outstanding shares, with institutional holders owning 44.31% of the shares at 44.47% float percentage. In total, 44.31% institutions holds shares in the company, led by BLACKROCK INC. As of 2024-06-30, the company held over 15.44 million shares (or 14.1544% of shares), all amounting to roughly $15.2 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 10.3 million shares, or about 9.4422% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $10.14 million.
